• Home
  • NEW DAY MEDICINE
  • 4 (66) 2024
  • 79 -4 (66) 2024 - Khaidarova F.A., Inogamova D.T. - STATE OF CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE AND RELATIONSHIP WITH VARIOUS LABORATORY INDICATORS

79 -4 (66) 2024 - Khaidarova F.A., Inogamova D.T. - STATE OF CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE AND RELATIONSHIP WITH VARIOUS LABORATORY INDICATORS

STATE OF CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE AND RELATIONSHIP WITH VARIOUS LABORATORY INDICATORS

Khaidarova F.A. Republican Specialized Scientific and Practical Medical Center of Endocrinology of the Ministry of Health of the Republic of Uzbekistan named after academician. Y.H. Turakulova, diabetic foot department, Republic of Uzbekista

Inogamova D.T. Republican Specialized Scientific and Practical Medical Center of Endocrinology of the Ministry of Health of the Republic of Uzbekistan named after academician. Y.H. Turakulova, diabetic foot department, Republic of Uzbekista

Resume

The purpose of the study is to study the state of central hemodynamics in patients with CHF with and without DM2 in comparison with other indicators. Material and research methods. 60 patients with DM 2 and chronic heart failure (CHF) were examined (prospectively) in the period 2021-2022 in the Acad surgery center. V.V. Vakhidov on the basis of a scientific agreement together with the RSSPMCE PHM RUZ named after Acad. Yo.Kh. Turakulov. All observed patients were divided into 2 groups: 1 gr. - 30 patients with heart failure and DM2 subjected to AKSh 2 gr. - 30 patients with heart failure without DM2 subjected to AKSh The control group will be 20 healthy persons. To characterize the examined patients will be used: general clinical, biochemical and instrumental examinations. Results. , In patients with heart failure without DM2, the level of blood glucose and the noma index were reliably lower in comparison with patients with DM2 +CHF. The average value of BMI in groups differed slightly, but between the CHF and DM2+ CHF group, the difference was statistically reliable. Conclusions. In patients of the DM2 + CHF group and CHF reliable differences in the average indicators of age, BMI, glycemia, the values of insulin, and the Homa index were not found depending on the values of the left ventricular emission faction. At the same time, the reliability of the differences was revealed only according to Galelectin 3: these values increased significantly as FV decreased in patients with diabetes + CHA. (p <0.05).

Keywords:diabetes mellitus 2 type 2, heart failure, left ventricular ejection fraction, galectin-3

First page

442

Last page

447

For citation: Khaidarova F.A., Inogamova D.T. - STATE OF CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE AND RELATIONSHIP WITH VARIOUS LABORATORY INDICATORS//New Day in Medicine 4(66)2024 442-447 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Курята А.В, Кушнир Ю.С. Уровень и динамика Галектина-3 при хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка на фоне использования петлевых диуретиков // https://www.webcardio.org/urovenj-y-dynamyka-ghalektyna-3-pry-khronycheskoj-serdechnoj-nedostatochnosty-s-sokhranennoj-systolycheskoj-funktsyej-levogho-zheludochka-na-fone-yspoljzovanyya-petlevykh-dyuretykov.aspx
  2. Щукин Ю. Вн, И. И. Березин, Е. А. Медведева, Е. И. Селезнев, В. А. Дьячков, Л. Н. Слатова. О значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных хронической сердечной недостаточность Юhttps://doi.org/10.15829/1560-4071-2013-2-45-49
  3. Целуйко В.И., Лозовая Т.А., Сасюк О.С. Галектин-3 как фактор риска неблагоприятных сердечно-сосудистых событий при долгосрочном наблюдении у больных с инфарктом миокарда правого желудочка на фоне q-инфаркта миокарда задней стенки левого желудочка // Журнал «медицина неотложных состояний» 2015 6 (69) http://www.mif-ua.com/archive/article/42272
  4. Abuelo G. J. Normotensive Ischemic Acute Renal Failure / G. J. Abuelo // N. Engl. J. Med. 2007; 357:797 - 805.
  5. Biscetti Federico, Elisabetta Nardella, Maria Margherita Rando, Andrea Leonardo Cecchini, et all. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study // Cardiovasc Diabetol. 2020; 19: 170. Published online 2020 Oct 7. doi: 10.1186/s12933-020-01151-z
  6. Savarese G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology // Cardiovascular research. 2022; 118(17):3272-3287.
  7. Groenewegen A , Rutten FH , Mosterd A , et al Epidemiology of heart failure. // Eur J Heart Fail 2020; 22:1342–56. doi:10.1002/ejhf.1858
  8. Conrad N , Judge A , Tran J , et al Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. // Lancet 2018;391:572–80. doi:10.1016/S0140-6736(17)32520-5
  9. Dunlay SM , Roger VL , Redfield MM . Epidemiology of heart failure with preserved ejection fraction. // Nat Rev Cardiol 2017;14:591–602. doi:10.1038/nrcardio.2017.65
  10. van Heerebeek L , Paulus WJ Understanding heart failure with preserved ejection fraction: where are we today? // Neth Heart J 2016;24:227–36. doi:10.1007/s12471-016-0810-1
  11. Pieske B, Tschöpe C , de Boer RA , et al How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of cardiology (ESC). // Eur Heart J 2019;40:3297–317.
  12. Borlaug BA , Redfield M.M. Diastolic and systolic heart failure phenotypes of the heart failuresyndrome. Circulation 2011;123:200613. doi:10.1161/Circulationaha.110.954388
  13. Pfeffer MA , Shah AM , Borlaug BA Heart failure with preserved ejection fraction in perspective. Circ Res 2019;124:1598–617. doi:10.1161/CIRCRESAHA.119.313572
  14. Heidenreich PA, Bozkurt B, Aguilar D, et al .2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of cardiology/american heart association joint Committee on clinical practice guidelines. Circulation 2022;145:e895-1032. doi:10.1161/CIR.0000000000001063

    file

    download